Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 295 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:20 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 27, 2024 | Feb 27, 2023 | Feb 28, 2022 |
| Revenue | $0 | $0 | $330.5M | $108.5M | $48.7M |
| Operating expenses | $555.3M | $501.9M | $527.2M | $449.2M | $344.4M |
| Research and development | $418.8M | $396.4M | $423.9M | $358.7M | $265.4M |
| Selling, general and administrative | $136.6M | $105.4M | $103.4M | $90.5M | $79.1M |
| Operating income | -$555.3M | -$487.3M | -$196.7M | -$340.7M | -$295.8M |
| Income tax | $102.0K | $68.0K | $30.0K | $21.0K | -$575.0K |
| Net income | -$512.5M | -$422.8M | -$145.2M | -$326.0M | -$290.6M |
| EPS, basic | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 |
| EPS, diluted | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 |
| Weighted shares, basic | 172.6M | 164.5M | 137.4M | 125.5M | 121.5M |
| Weighted shares, diluted | 172.6M | 164.5M | 137.4M | 125.5M | 121.5M |
| Margins and growth | |||||
| Operating margin | – | – | -59.5% | -314.2% | -607.8% |
| Net margin | – | – | -43.9% | -300.6% | -597.2% |
| Revenue growth, year over year | – | −100.0% | +204.7% | +122.9% | −85.5% |
| Net income growth, year over year | – | – | – | – | −508.5% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 27, 2024 | Feb 27, 2023 | Feb 28, 2022 |
| Cash and equivalents | $205.3M | $175.0M | $127.1M | $218.0M | $293.5M |
| Short-term investments | $662.6M | $657.4M | $907.4M | $1.12B | $571.9M |
| Total current assets | $900.7M | $864.4M | $1.06B | $1.37B | $897.2M |
| Property, plant and equipment | $52.4M | $55.2M | $45.6M | $44.1M | $38.9M |
| Total assets | $1.14B | $1.37B | $1.15B | $1.46B | $1.40B |
| Accounts payable | $3.33M | $11.1M | $9.48M | $2.79M | $4.78M |
| Total current liabilities | $98.4M | $102.2M | $78.0M | $363.9M | $378.2M |
| Total liabilities | $131.1M | $144.5M | $123.0M | $417.8M | $441.9M |
| Shareholders' equity | $1.01B | $1.23B | $1.03B | $1.04B | $962.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 27, 2024 | Feb 27, 2023 | Feb 28, 2022 |
| Operating cash flow | -$412.6M | -$347.7M | -$358.0M | -$244.7M | -$211.4M |
| Capital expenditures | $9.50M | $15.9M | $12.9M | $17.8M | $8.50M |
| Free cash flow | -$422.1M | -$363.6M | -$370.9M | -$262.5M | -$219.9M |
| Depreciation and amortization | $11.2M | $7.79M | $16.7M | $10.4M | $8.59M |
| Stock-based compensation | $99.6M | $102.9M | $108.1M | $99.8M | $85.2M |
| Investing cash flow | $255.3M | -$88.8M | $249.3M | -$141.4M | -$21.6M |
| Financing cash flow | $189.2M | $484.3M | $17.8M | $310.7M | $19.3M |
| Net change in cash | $31.9M | $47.9M | -$90.9M | -$75.4M | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | 32.7% | 92.1% | 175.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 28, 2026 | 160.3M | +9.3% | SEC |
| Jul 31, 2026 | 159.8M | +9.3% | SEC |
| May 1, 2026 | 158.7M | +9.2% | SEC |
| Feb 20, 2026 | 158.6M | +9.2% | SEC |
| Oct 31, 2025 | 146.7M | +1.9% | SEC |
| Aug 5, 2025 | 146.2M | +2.1% | SEC |
| Apr 30, 2025 | 145.3M | +1.9% | SEC |
| Feb 21, 2025 | 145.2M | +4.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.